Elanco Animal Health Incorporated ELAN NYSE

Elanco Animal Health Incorporated (ELAN) reported total assets of $13.36B and total liabilities of $6.81B for fiscal year 2025, resulting in total equity of $6.55B.

The company held $545M in cash and short-term investments. Total debt stood at $4.02B, with net debt of $3.47B. The Debt-to-Equity (D/E) ratio was 0.61 (moderate).

Current ratio is 2.17, indicating strong short-term liquidity. Interest coverage is 1.1x (weak).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (58/100) — Total assets $13.36B and equity $6.55B support the company's competitive scale
• VALUE (86/100) — Debt-to-Equity 0.61 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 48/100 with 2/7 criteria passed.

HLN

Haleon plc

$9.70

-1.32%

TEVA

Teva Pharmaceutical Industries Limited

$31.77

+1.99%

RVMD

Revolution Medicines, Inc.

$147.01

+7.86%

VTRS

Viatris Inc.

$13.91

+0.58%

ITCI

Intra-Cellular Therapies, Inc.

$131.87

+0.00%

ALGN

Align Technology, Inc.

$184.69

+2.23%

NBIX

Neurocrine Biosciences, Inc.

$130.81

+3.55%

SOLV

Solventum Corporation

$69.02

+2.39%